PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.275
-0.050 (-3.77%)
At close: Nov 5, 2026, 4:00 PM EST
1.300
+0.025 (1.96%)
After-hours: Nov 5, 2026, 4:59 PM EST
Company Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.
PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
PMV Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2013 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | David Mack |
Contact Details
Address: 400 Alexander Park Drive, Suite 301 Princeton, New Jersey 08540 United States | |
| Phone | 609 642 6670 |
| Website | pmvpharma.com |
Stock Details
| Ticker Symbol | PMVP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1699382 |
| CUSIP Number | 69353Y103 |
| ISIN Number | US69353Y1038 |
| Employer ID | 46-3218129 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Independent Director and Member of Scientific Advisory Board |
| Robert Ticktin J.D. | General Counsel, Chief Operating Officer and Company Secretary |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Michael Carulli | Chief Financial Officer and Principal Financial & Accounting Officer |
| Tim Smith M.B.A. | Senior Vice President and Head of Corporate Development and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 5, 2026 | 8-K | Current Report |
| Sep 15, 2026 | SCHEDULE 13G | Filing |
| Sep 2, 2026 | 8-K | Current Report |
| Sep 2, 2026 | 424B5 | Filing |
| Aug 31, 2026 | 424B3 | Prospectus |
| Aug 31, 2026 | 424B5 | Filing |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Jul 28, 2026 | SCHEDULE 13G/A | Filing |